Mar Vista Investment Partners LLC Boosts Holdings in Johnson & Johnson (JNJ)

Mar Vista Investment Partners LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 388,324 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Johnson & Johnson accounts for about 2.1% of Mar Vista Investment Partners LLC’s portfolio, making the stock its 22nd largest position. Mar Vista Investment Partners LLC’s holdings in Johnson & Johnson were worth $50,486,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Harding Loevner LP acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $177,000. 65.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of Johnson & Johnson (JNJ) opened at $131.23 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $117.00 and a 12 month high of $148.32. The company has a market cap of $352,550.00, a P/E ratio of 336.49, a price-to-earnings-growth ratio of 2.33 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same period in the previous year, the business posted $1.58 EPS. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.56%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 861.54%.

JNJ has been the subject of a number of recent analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research note on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Citigroup lifted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $146.16.

TRADEMARK VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://weekherald.com/2018/02/16/mar-vista-investment-partners-llc-boosts-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply